Hwang, Wei-Ting
Mayo Clinic
Department of Biostatistics, Epidemiology, and Informatics, The University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Citations 1
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Razzo, Beatrice M. , Midha, Shonali , Portuguese, Andrew J. , Grajales‐Cruz, Ariel , Corraes, Andre De Menezes Silva , Costello, Patrick , Liu, Yuxin , Sperling, Adam S. , Nadeem, Omar , Dima, Danai , Cowan, Andrew J. , Afrough, Aimaz , Anderson, Larry D. , Goyal, Anmol , Ferreri, Christopher J. , Voorhees, Peter M. , Patel, Krina K. , Julian, Kelley , Forsberg, Peter A. , Susanibar-Adaniya, Sandra P. , Khouri, Jack , Raza, Shahzad , Vazquez‐Martinez, Mariola , Sborov, Douglas W. , Davis, James A. , Shune, Leyla , Bhurtel, Jenny , Hwang, Wei‐Ting , Sidana, Surbhi , Grajales-Cruz, Ariel F , De Menezes Silva Corraes, Andre , Banerjee, Rahul , Cowan, Andrew J , Afrough, Aimaz , Anderson, Larry D , Lieberman-Cribbin, Alex , Kaur, Gurbakhash , Goyal, Anmol , Atrash, Shebli , Ferreri, Christopher , Voorhees, Peter , Pasvolsky, Oren , Lee, Hans C , Patel, Krina , Julian, Kelley L , Forsberg, Peter A , Herr, Megan M. , Chhabra, Saurabh , Parrondo, Ricardo D , Lin, Yi , Chen, Anna , Susanibar-Adaniya, Sandra P , Khouri, Jack , Raza, Shahzad , Anwer, Faiz , Vazquez-Martinez, Mariola A , Castaneda Puglianini, Omar , Sborov, Douglas W , Davis, James A , Rossi, Adriana , Shune, Leyla , Bhurtel, Evguenia , Hwang, Wei-Ting , Hansen, Doris K , Sidana, Surbhi , Garfall, Alfred L , Richard, Shambavi , Nadeem, Omar , Dima, Danai , Sperling, Adam S , Portuguese, Andrew J , Banerjee, Rahul , Kaur, Gurbakhash , Atrash, Shebli , Pasvolsky, Oren , Lee, Hans C. , Chhabra, Saurabh , Lin, Yi , Anwer, Faiz , Puglianini, Omar Castañeda , Rossi, Adriana , Hansen, Doris K. , Garfall, Alfred L. , Richard, Shambavi
Blood Cancer Discovery | July 9, 2025 | Volume: 6 | Issue: 6 | Pages: 561-571
Abstract Teclistamab is an anti-CD3-/B-cell maturation antigen (BCMA) bispecific antibody approved for use in relapsed/refractory multiple myeloma. We undertook a retrospective study of post-approval, real-world outcomes with teclistamab in the US Multiple Myeloma Immunotherapy Consortium. Among 509 patients, 89% would have been ineligible for the MajesTEC-1 trial, primarily due to prior BCMA-directed therapy, cytopenias, or diminished performance status. Cytokine release syndrome occurred in 54% (1.4% grade ≥3) and immune effector cell–associated neurotoxicity syndrome in 11% (2.2% grade ≥3), with no fatal events. Infections occurred in 42% and contributed to death in 5%. Partial response (PR) or better was achieved in 53% and very good PR or better in 45%. With 10.1 months of median follow-up, the estimated median progression-free survival (PFS) was 5.8 months and 12-month overall survival was 61%. Independent predictors of less than very good PR and shorter PFS included BCMA-directed chimeric antigen receptor T-cell therapy in the previous 9 months, high disease burden, lymphopenia, and elevated ferritin. Significance: T cell–engaging bispecific antibodies such as teclistamab represent an important new treatment modality for multiple myeloma and other blood cancers. This study evaluates the real-world safety and efficacy of teclistamab, including its activity in populations not represented in the initial phase I/II study, and identifies clinical variables associated with treatment response. See related commentary by Zweegman et al., p. 542